First Trust Advisors’s Ginkgo Bioworks DNA Stock Holding History

First Trust Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,832	Closed	-$350K	–	2360
2023 Q3	$350K	Buy	+4,832	New	+$386K	﹤0.01%	2220
2023 Q1	–	Sell	-103,021	Closed	-$6.96M	–	2383
2022 Q4	$6.96M	Buy	+103,021	New	+$9.48M	0.01%	1069

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors's DNA Position: Q4 2023 in Review

First Trust Advisors sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 4,832 shares — an estimated $350K sold.

First Trust Advisors first reported a position in DNA in Q4 2022 and held it in 2 quarters. The position peaked at $6.96M in Q4 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

First Trust Advisors reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
First Trust Advisors sold 4,832 Ginkgo Bioworks shares in Q4 2023, an estimated $350K.
First Trust Advisors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 2 quarters.
First Trust Advisors's Ginkgo Bioworks position peaked at $6.96M in Q4 2022.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on First Trust Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.